Cancer-drug company Celgene Corp. said it will pay $7.2 billion for biotech company Receptos Inc. in a bid to move deeper into the multibillion-dollar market for autoimmune diseases.

Celgene Corp. is in talks to buy biotechnology company Juno Therapeutics Inc., just days after announcing another major deal to bolster its portfolio of blood-cancer drugs.

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Celgene Corporation recently completed a Phase 3B study titled ...

Celgene Corp. (CELG) was once a biotech darling, with its stock rising by approximately 150 percent over the past five years. But the shares have fallen off a cliff in recent months, down by ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could ...

Celgene has had a difficult time recently as a result of the company decreasing its 2020 estimates. However, the company still has an incredibly strong portfolio. Celgene anticipates that it will ...

Celgene Corp. agreed to buy San Diego firm Impact Biomedicines for $1.1 billion upfront to gain an experimental blood cancer treatment.

Celgene's forward price-to-earnings multiple currently stands at 0.79. That's cheap. Of course, forward multiples like this rely on future growth estimates.

In the first megablockbuster deal of the year, Bristol-Myers Squibb takes out oncology giant Celgene in a deal worth $74 billion. Celgene's stock is skyrocketing today in response to a megamerger ...

Over the past seven years, Celgene has emerged as one of the most active and creative deal-makers in the biopharma industry. The Boston Consulting Group’s Biopharma Partnering Survey and ...